Sangamo Therapeutics (NASDAQ:SGMO) Given New $9.00 Price Target at Barclays

Sangamo Therapeutics (NASDAQ:SGMO) had its price objective upped by Barclays from $3.00 to $9.00 in a research note published on Thursday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on SGMO. StockNews.com assumed coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They set a “sell” rating for the company. HC Wainwright raised their price target on Sangamo Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, November 5th.

Sangamo Therapeutics Stock Down 4.2 %

Shares of Sangamo Therapeutics stock traded down $0.09 on Thursday, reaching $2.06. The company’s stock had a trading volume of 3,898,286 shares, compared to its average volume of 6,916,520. The company has a market capitalization of $429.76 million, a price-to-earnings ratio of -2.69 and a beta of 1.10. The firm’s fifty day simple moving average is $1.30 and its two-hundred day simple moving average is $0.85. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18.

Institutional Investors Weigh In On Sangamo Therapeutics

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its holdings in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after buying an additional 1,528,600 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sangamo Therapeutics in the first quarter valued at $331,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Sangamo Therapeutics during the second quarter worth about $89,000. Vontobel Holding Ltd. raised its position in Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in Sangamo Therapeutics by 56.3% in the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 207,476 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.